» Articles » PMID: 32131757

Serum-to-urine Renalase Ratio and Renalase Fractional Excretion in Healthy Adults and Chronic Kidney Disease Patients

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2020 Mar 6
PMID 32131757
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renalase is a flavoprotein that plays a protective role in chronic kidney disease (CKD) and cardiovascular diseases. The secretion and way of action of this protein are still discussed. The aim of our study was to estimate the balance between serum and urine renalase in healthy individuals and CKD patients, using two parameters: fractional excretion (FE) and serum-to-urine renalase ratio (StURR).

Methods: Our study involved 28 healthy volunteers and 62 patients with CKD in stages I to IV. The concentration of renalase in serum and urine was measured using an enzyme-linked immunosorbent assay (ELISA) kit (EIAab, Wuhan, China). We analyzed associations between renalase levels in urine and serum, and other parameters: sex, age, GFR, presence of hypertension, diabetes, and proteinuria, and determined the serum-to-urine renalase ratio and fractional excretion of renalase.

Results: Renalase and serum-to-urine ratio were significantly higher in CKD patients in comparison with the control group. Fractional excretion was lower in CKD patients but this difference did not reach the statistical significance (p = 0.092). Multivariate analysis performed in the CKD group showed, that from mentioned parameters, serum renalase was the only significant independent factor strongly positively associated with urinary renalase concentration.

Conclusions: The serum-to-urine ratio is significantly and about 6.5-fold higher in CKD patients, and the fractional excretion of renalase is 3-fold, but not significantly lower in CKD patients. Renalase levels in both serum and urine are not related to the glomerular filtration rate and not associated with blood pressure.

Citing Articles

Renalase Potential as a Marker and Therapeutic Target in Chronic Kidney Disease.

Serban-Feier L, Cuiban E, Gogosoiu E, Stepan E, Radulescu D Biomedicines. 2024; 12(8).

PMID: 39200179 PMC: 11351300. DOI: 10.3390/biomedicines12081715.


Renal and Inflammation Markers-Renalase, Cystatin C, and NGAL Levels in Asymptomatic and Symptomatic SARS-CoV-2 Infection in a One-Month Follow-Up Study.

Serwin N, Cecerska-Heryc E, Pius-Sadowska E, Serwin K, Niedzwiedz A, Wisniewska M Diagnostics (Basel). 2022; 12(1).

PMID: 35054276 PMC: 8774569. DOI: 10.3390/diagnostics12010108.


Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study.

Cerqueira A, Quelhas-Santos J, Ferreira I, Sampaio S, Relvas M, Marques N Life (Basel). 2021; 11(3).

PMID: 33800219 PMC: 7999882. DOI: 10.3390/life11030210.

References
1.
Desir G . Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Curr Opin Nephrol Hypertens. 2008; 17(2):181-5. DOI: 10.1097/MNH.0b013e3282f521ba. View

2.
Rybi-Szuminska A, Michaluk-Skutnik J, Osipiuk-Remza B, Kossakowska A, Wasilewska A . Normal values for urine renalase excretion in children. Pediatr Nephrol. 2014; 29(11):2191-5. PMC: 4176974. DOI: 10.1007/s00467-014-2855-y. View

3.
Wang F, Xing T, Li J, Bai M, Hu R, Zhao Z . Renalase's expression and distribution in renal tissue and cells. PLoS One. 2012; 7(10):e46442. PMC: 3463591. DOI: 10.1371/journal.pone.0046442. View

4.
Wang L, Velazquez H, Chang J, Safirstein R, Desir G . Identification of a receptor for extracellular renalase. PLoS One. 2015; 10(4):e0122932. PMC: 4407985. DOI: 10.1371/journal.pone.0122932. View

5.
Gluba-Brzozka A, Michalska-Kasiczak M, Franczyk-Skora B, Nocun M, Banach M, Rysz J . Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids Health Dis. 2014; 13:135. PMC: 4246537. DOI: 10.1186/1476-511X-13-135. View